APLS

26.18

0.34% -0.09

Handel nachbörslich: 28.18 2.00 +7.64%

Apellis Pharmaceuticals Inc (APLS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt APLS? Forum Prognose

Schlusskurs vom Vortag:

$26.27

Offen:

$26.45

24-Stunden-Volumen:

7.62M

Relative Volume:

3.04

Marktkapitalisierung:

$3.26B

Einnahmen:

$715.22M

Nettoeinkommen (Verlust:

$-250.10M

KGV:

-4.9867

EPS:

-5.25

Netto-Cashflow:

$-205.58M

1W Leistung:

-11.49%

1M Leistung:

-6.50%

6M Leistung:

-36.63%

1J Leistung:

-46.68%

1-Tages-Spanne:

$25.76

$26.66

1-Wochen-Bereich:

$25.76

$29.94

52-Wochen-Spanne:

$24.34

$73.80

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Firmenname

Apellis Pharmaceuticals Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

617-977-5700

Adresse

100 FIFTH AVENUE, WALTHAM, KY

Mitarbeiter

702

Twitter

@ApellisPharma

Nächster Verdiensttermin

2024-12-05

Neueste SEC-Einreichungen

APLS's Discussions on Twitter

Vergleichen Sie APLS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
APLS	26.18	3.26B	715.22M	-250.10M	-205.58M	-5.25
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-02-05	Hochstufung	Jefferies	Hold → Buy
2023-12-14	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-11-09	Eingeleitet	Goldman	Buy
2023-11-02	Eingeleitet	Mizuho	Neutral
2023-10-06	Hochstufung	JP Morgan	Neutral → Overweight
2023-09-15	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-08-29	Bestätigt	Citigroup	Buy
2023-08-03	Herabstufung	JP Morgan	Overweight → Neutral
2023-08-01	Herabstufung	BofA Securities	Buy → Neutral
2023-01-03	Herabstufung	Wells Fargo	Overweight → Equal Weight
2022-11-10	Herabstufung	Jefferies	Buy → Hold
2022-07-19	Eingeleitet	H.C. Wainwright	Buy
2022-06-17	Fortgesetzt	Stifel	Buy
2022-04-14	Herabstufung	ROTH Capital	Neutral → Sell
2021-12-08	Eingeleitet	Wells Fargo	Overweight
2021-11-29	Herabstufung	ROTH Capital	Buy → Neutral
2021-09-10	Bestätigt	BMO Capital Markets	Outperform
2021-09-10	Bestätigt	Credit Suisse	Neutral
2021-09-10	Bestätigt	Needham	Buy
2021-09-10	Bestätigt	Oppenheimer	Outperform
2021-09-10	Herabstufung	Wedbush	Outperform → Neutral
2021-08-19	Eingeleitet	Jefferies	Buy
2021-08-19	Hochstufung	Wedbush	Neutral → Outperform
2021-05-21	Eingeleitet	UBS	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2020-11-19	Eingeleitet	Needham	Buy
2020-09-01	Eingeleitet	Stifel	Buy
2020-07-20	Eingeleitet	ROTH Capital	Buy
2020-06-17	Eingeleitet	BTIG Research	Neutral
2020-04-01	Eingeleitet	Raymond James	Strong Buy
2020-03-31	Eingeleitet	BMO Capital Markets	Outperform
2020-03-11	Hochstufung	Wedbush	Underperform → Neutral
2020-01-07	Eingeleitet	SVB Leerink	Mkt Perform
2019-12-19	Eingeleitet	BofA/Merrill	Buy
2019-11-22	Eingeleitet	Wedbush	Underperform
2019-11-05	Eingeleitet	Credit Suisse	Neutral
2019-08-01	Bestätigt	Cantor Fitzgerald	Overweight
2019-07-12	Hochstufung	JP Morgan	Neutral → Overweight
2019-03-29	Eingeleitet	Robert W. Baird	Outperform
2019-01-23	Herabstufung	JP Morgan	Overweight → Neutral
2018-07-30	Hochstufung	B. Riley FBR	Neutral → Buy
2018-05-24	Eingeleitet	Cantor Fitzgerald	Overweight
2018-04-12	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-02-08	Eingeleitet	B. Riley FBR, Inc.	Buy

Alle ansehen

Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten

Nov 17, 2024

GSA Capital Partners LLP Purchases Shares of 28,584 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Nov 17, 2024

Nov 14, 2024

T. Rowe Price Investment Management Reduces Stake in Apellis Pha - GuruFocus.com

Nov 14, 2024

Nov 12, 2024

Apellis Pharmaceuticals to Present at Jefferies London Healthcare Conference 2024 | APLS Stock News - StockTitan

Nov 12, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference - The Manila Times

Nov 12, 2024

Nov 10, 2024

(APLS) Trading Signals - Stock Traders Daily

Nov 10, 2024

Nov 09, 2024

Fiera Capital Corp Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Nov 09, 2024

Nov 08, 2024

Wellington Management Group LLP Reduces Stake in Apellis Pharmac - GuruFocus.com

Nov 08, 2024

HC Wainwright Has Negative Outlook of APLS FY2024 Earnings - MarketBeat

Nov 08, 2024

William Blair Issues Pessimistic Forecast for APLS Earnings - MarketBeat

Nov 08, 2024

Nov 07, 2024

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript - MSN

Nov 07, 2024

Robert W. Baird Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat

Nov 07, 2024

Wedbush Cuts Earnings Estimates for Apellis Pharmaceuticals - MarketBeat

Nov 07, 2024

Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise By Investing.com - Investing.com Nigeria

Nov 07, 2024

Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise - Investing.com

Nov 07, 2024

Nov 06, 2024

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y - Barchart

Nov 06, 2024

Wells Fargo & Company Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $30.00 - MarketBeat

Nov 06, 2024

Old West Investment Management LLC Purchases Shares of 102,403 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat

Nov 06, 2024

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $32.00 by Analysts at Piper Sandler - MarketBeat

Nov 06, 2024

Needham & Company LLC Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $60.00 - MarketBeat

Nov 06, 2024

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $57.00 by Analysts at HC Wainwright - MarketBeat

Nov 06, 2024

Bank of America Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $47.00 - MarketBeat

Nov 06, 2024